HAENYSESurgical & Medical Instruments & ApparatusFiscal year ends April 3
HAEMONETICS CORP
Financials through Q1 FY2027, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 6, 2026
$118.73+0.45 (+0.38%)
Close on Oct 19, 2026
- Market cap
- $5.43B
- P/E (TTM)
- 57.9
- Dividend yield
- –
Share price
+$68.47 (+136.2%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
HAEMONETICS CORP grew revenue 0.4% to $1.35B over the twelve months to Jun 27, 2026. Operating income fell 32.0% to $160.32M, moving the operating margin from 17.5% to 11.9%. Free cash flow was $291.22M, up 53.9% from a year earlier.
Revenue
$1.35B
+0.4% vs. a year earlier
Operating income
$160.32M
-32.0% vs. a year earlier
Free cash flow
$291.22M
+53.9% vs. a year earlier
EPS, diluted
$2.05
-37.3% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 27, 2026
Valuation
- Market cap
- $5.43B
- P/E ratio
- 57.9
- Price to sales
- 4.01
- Price to book
- 6.48
- Dividend yield
- –
- Free cash flow yield
- 5.37%
Fundamentals
- Revenue
- $1.35B
- Net income
- $96.29M
- EPS, diluted
- $2.05
- Free cash flow
- $291.22M
- Book value per share
- $18.32
- Diluted shares
- 46M
Fifteen years at a glance
Fiscal years 2012 to 2026 and trailing twelve months, USD
Revenue
$1.35B+0.4% YoY
Gross profit
$798.15M+4.2% YoY
Operating income
$160.32M-32.0% YoY
Net income
$96.29M-41.1% YoY
EPS, diluted
$2.05-37.3% YoY
Free cash flow
$291.22M+53.9% YoY
Reported periodTrailing twelve months